28 results about "Chemotherapy effects" patented technology

The invention relates to the field of anti-tumor drugs, and discloses an anti-diffuse large B-cell lymphoma pharmaceutical composition, a preparation method and application thereof, the composition comprises azacitidine and Sanilisoma, the composition can improve the accumulation amount of VDUP1 protein in a cell nucleus through the combination of the methylation effect of DNMT3b on VDUP1 protein and the inhibition of XPO1 activity by Sanilisoma, and the anti-diffuse large B-cell lymphoma pharmaceutical composition can be used for preparing anti-diffuse large B-cell lymphoma. The chemotherapy effect is remarkably improved, the sensitivity of the DLBCL to the Sanisole is remarkably improved, and particularly, the pharmaceutical composition has a remarkable curative effect on R / R DLBCL patients.

The invention discloses an EGFR (epidermal growth factor receptor) targeted nano-drug carrier and a preparation method thereof, the EGFR targeted nano-drug carrier comprises drug-loading nanoparticles, an erythrocyte membrane coating the drug-loading nanoparticles and GE11 peptide connected to the erythrocyte membrane, and the drug-loading nanoparticles are formed by connecting tannic acid, ellagic acid and 1, 4-phenyldiboronic acid through boric acid ester bonds. The EGFR targeted nano-drug carrier disclosed by the invention can be enriched at an EGFR overexpressed tumor site in a targeted manner, and can be effectively prevented from being cleared by an immune system, and the drug loaded by the drug-loaded nanoparticles is released in a high-active oxygen environment, so that the treatment effect on tumors can be improved, and the toxic and side effects on normal tissues can be reduced; and photothermal therapy and chemotherapy effects can be simultaneously generated under NIR illumination, and the anticancer efficiency can be remarkably improved through the synergistic effect of the photothermal therapy and the chemotherapy.

The invention discloses a grifola frondosa-derived exosome-like nano-vesicle as well as an extraction method and application thereof. The extraction method comprises the following steps: cutting pilei and stipes of grifola frondosa, and grinding with a proper amount of cold PBS to prepare grifola frondosa bacterial juice; the grifola frondosa juice is centrifuged at 500 g-1, 000 g, sediment is discarded, the obtained supernatant is centrifuged at 2,000 g-3,000 g, sediment is discarded, the obtained supernatant is centrifuged at 10,000 g-12,000 g, sediment is discarded, the obtained supernatant is filtered, and the pretreated grifola frondosa juice is obtained; and centrifuging the pretreated grifola frondosa juice at 30,000-100,000 g for 30 minutes to 4 hours, and resuspending by using PBS (Phosphate Buffer Solution), so as to obtain the grifola frondosa-derived exosome-like nano-vesicles. The invention develops a new thought for the mechanism of cancer inhibition, chemotherapy effect enhancement and flora regulation of the grifola frondosa, and lays a foundation for application of the grifola frondosa in development of products such as related foods, functional foods, health foods, medicines and gel-loaded medicines.

The invention relates to a hybrid nano assembly for dual synergistic chemotherapy as well as a preparation method and application of the hybrid nano assembly, and belongs to the technical field of pharmaceutical preparations. The invention relates to a hybrid nano assembly for dual synergistic chemotherapy, which is formed by co-assembling a cabazitaxel prodrug and gossypol under hydrophobic action and hydrogen bond driving, and is modified by adopting a PEG (Polyethylene Glycol) modifier, the molar ratio of the cabazitaxel prodrug to the gossypol is 1: (1-7), and the ratio of the total mass of the cabazitaxel prodrug and the gossypol to the mass of the PEG modifier is 4: 1. A cabazitaxel prodrug and a sensitizer gossypol are co-assembled to obtain a hybrid nano assembly, the hybrid nano assembly is oxygenated to obtain the oxygen-carrying preparation, the nano assembly and the oxygen-carrying preparation are simple and convenient to prepare and high in drug loading efficiency, and efficient co-loading of drugs can be achieved; meanwhile, the curative effect of chemotherapy can be enhanced through dual mechanisms of relieving tumor hypoxia and promoting tumor apoptosis, and the pharmaceutical composition has a good clinical application prospect.

This invention discloses a multifunctional tumor-targeted cryotherapy nanoplatform and its applications, belonging to the field of nanobiomedicine technology. The multifunctional tumor-targeted cryotherapy nanoplatform of this invention uses two-dimensional Ti3C2 nanomaterials as a carrier, loaded with indocyanine green as a photosensitizer, surface-modified with polydopamine to improve stability, and loaded with gambogeylic acid as an anti-tumor drug and a heat shock protein inhibitor. It is covalently coupled with nucleic acid aptamers that can recognize cell surface-specific proteins. The multifunctional tumor-targeted cryotherapy nanoplatform has small particle size, high dispersion, and good biocompatibility, and exhibits excellent photothermal conversion ability, photodynamic therapy effect, and chemotherapy effect in tumor-targeted therapy. It can effectively induce tumor cell apoptosis under relatively low temperature conditions, significantly reducing the damage of high temperature to surrounding healthy tissues. It also has the ability to specifically recognize tumor lesions, achieving high enrichment at the tumor site and enhancing the therapeutic effect.

The application discloses Lactobacillus reuteri and application thereof in preparation of a medicine for treating diffuse large B-cell lymphoma, and relates to the technical field of biological medicine. The application provides application of Lactobacillus reuteri and / or a metabolite thereof in preparation of a medicine for treating diffuse large B-cell lymphoma, wherein the Lactobacillus reuteri is Lactobacillus reuteri (HG001). Limosilactobacillus reuteri The Lactobacillus reuteri is separated from feces of healthy people and used for preparation of the medicine for treating diffuse large B-cell lymphoma, and it is found that the Lactobacillus reuteri is confirmed as a probiotic strain for enhancing the chemotherapy effect of diffuse large B-cell lymphoma and can improve side effects caused by cyclophosphamide treatment of diffuse large B-cell lymphoma; and the Lactobacillus reuteri and the cyclophosphamide have a synergistic effect in treatment of diffuse large B-cell lymphoma.

The invention relates to the technical field of biological medicines, and particularly discloses a high-grade serous ovarian cancer (HGSOC) treatment strategy based on ANXA6 protein detection and regulation. The invention provides a method for evaluating the sensitivity of a patient to cisplatin chemotherapy by detecting the expression level of ANXA6 protein or a specific modification site thereof, and a composition comprising inhibiting the function of ANXA6 or combining with cisplatin. In addition, the invention also relates to a medicine application for enhancing the chemotherapy effect by regulating the activity of ANXA6 related modifying enzyme.

The application discloses a polymer vesicle-stabilized drug-iodized oil emulsion and a preparation method and application thereof, to realize safe and efficient transarterial chemoembolization (TACE) treatment of hepatocellular carcinoma in situ. The drug-iodized oil emulsion system has the following advantages: simple preparation, convenient size adjustment, excellent stability, near-zero order and sustained controllable drug release rate, low blood drug concentration after transarterial embolization, and the retention time and retention amount of the drug in the liver are superior to those of free drug-iodized oil emulsion used in clinical treatment, the tumor can be completely eradicated, angiogenesis can be effectively inhibited, and adverse reactions can be reduced. In general, the polymer vesicle-stabilized drug-iodized oil emulsion has the advantages of high stability and sustained controllable drug release, and can greatly improve the embolization chemotherapy effect of hepatocellular carcinoma, and provide a safe and efficient TACE strategy.

The invention belongs to the technical field of biological medicine, and particularly relates to application of REXO4 interference polypeptide in tumor treatment. It is found for the first time that the REXO4 interference polypeptide can inhibit breast cancer tumor cell proliferation, promote chemotherapy drug-induced DNA damage and improve the breast cancer chemotherapy effect, in addition, through combination of the REXO4 interference polypeptide and Olaparib, the remarkable synergistic anti-tumor effect can be shown, and the effect is better than that of single medication. The invention also finds that the REXO4 interference polypeptide can reverse the drug resistance of breast cancer to chemotherapeutic drugs, and a brand new solution is provided for overcoming the drug resistance of PARP inhibitors.

The utility model discloses a tumor local thermochemotherapy device which comprises a support and a thermochemotherapy device body, the thermochemotherapy device body is fixedly connected to the front end of the support, the front end of the support is fixedly connected with a connecting plate, the front end of the connecting plate is movably connected with a connecting column, the outer side of the connecting column is movably connected with two sets of fixing clamps, and the fixing clamps are fixedly connected with the support. And the two groups of fixing clamps are mutually symmetrical. According to the tumor local thermochemotherapy device, the chemotherapy device can be conveniently transferred, and meanwhile, the chemotherapy device can be fixed to a sickbed, so that the situation that the chemotherapy effect is affected due to deviation in the chemotherapy process is avoided.

The invention provides a pharmaceutical composition and application thereof in preparation of medicines for treating ovarian cancer, and the pharmaceutical composition is prepared from the following components in parts by weight: 5-20 parts of cortex phellodendri, 5-20 parts of rhizoma atractylodis, 5-20 parts of radix achyranthis bidentatae, 5-20 parts of oldenlandia diffusa, 5-20 parts of radix trichosanthis, 5-20 parts of cassia twig, 20-40 parts of radix astragali and 20-40 parts of semen coicis. The pharmaceutical composition provided by the invention is suitable for ovarian cancer postoperative combined chemotherapy, and can significantly reduce the incidence rate of adverse reactions of chemotherapy, improve the chemotherapy effect and compliance, and reduce the toxic and side effects of chemotherapy drugs.

The invention belongs to the technical field of blood disease diagnosis, and provides a noninvasive screening method for acute B lymphocytic leukemia (B-ALL) based on a peripheral blood CD3 + CD19 + double positive cell subset, which comprises the following steps: detecting the proportion of CD3 + CD19 + double positive cells in peripheral blood through flow cytometry, and comparing the proportion with a proportion threshold in a positive judgment standard for judgment; when the detection result is greater than or equal to 0.20%, judging that the sample is positive; cD3 + CD19 + double positive cells exist in B-ALL peripheral blood, the detection rate of B-ALL peripheral blood in peripheral blood of healthy people and other types of leukemia patients is extremely low, and the B-ALL has high specificity; compared with bone marrow puncture and other invasive diagnosis methods, the non-invasive primary screening of B-ALL is realized, and the problem of insufficient specificity of the existing non-invasive detection technology is overcome; the kit is suitable for early screening of children B-ALL, dynamic monitoring of chemotherapy curative effect and prognosis evaluation, and has important clinical application value.

The invention discloses a precise tumor chemoradiotherapy drug delivery device, which relates to the technical field of medical instruments, and comprises an injection host and a high-precision peristaltic pump mounted in the injection host, and further comprises a drug storage mechanism, a movable loosening and clamping assembly and a leakage detection assembly. During use, three independent cabin seats are arranged in the medicine storage mechanism, three medicine storage devices are clamped in the three independent cabin seats respectively, loading of three chemotherapeutic medicines can be completed in advance, frequent replacement of medicine storage cylinders is not needed, ordered infusion of the three medicines is achieved through opening and closing of a controllable communication valve in the gathering pipeline assembly, the treatment time is shortened, infusion continuity is improved, and the treatment efficiency is improved. In addition, in the medicine injection process, all the sensors detect medicine leakage, pipeline blockage, bubbles and medicine stock in real time, and precise medicine conveying is achieved. And a clamping mechanism is arranged in the module cabin body assembly, so that the medicine storage cylinder can be quickly disassembled and assembled, and the operation is simple and convenient.

The invention discloses a research method for promoting glioblastoma drug resistance by regulating YAP through P4HA1, and relates to the technical field of biology. The invention aims at researching whether P4HA1 has hydroxylation on YAP, so that the drug resistance of GBM to TMZ is influenced, and finally the proliferation condition of GBM is influenced, further exploring whether the treatment resistance of GBM can be improved after a P4HA1 inhibitor and a YAP inhibitor are combined with TMZ, and evaluating the possibility that P4HA1 and YAP are used as potential treatment targets by understanding the interaction between P4HA1 and YAP. According to the invention, a new treatment method capable of overcoming the drug resistance of GBM chemotherapy is found, the chemotherapy effect is improved, so that the prognosis of a patient is improved, the influence of P4HA1 and YAP on the drug sensitivity of GBM is innovatively evaluated, a new treatment strategy is provided for overcoming the clinical drug resistance problem, and potential signal channels and molecular targets are found.

The application relates to the field of medicine, in particular to the application of 4-hydroxyphenylacetic acid and irinotecan as cancer chemotherapy drugs. In view of the technical defects that the existing irinotecan chemotherapy hepatoprotective drugs have single action and may interfere with the chemotherapy effect, the application provides the application of 4-hydroxyphenylacetic acid and irinotecan in the preparation of cancer chemotherapy drugs. The application has the following advantages: 1. clear hepatoprotective effect: 4HPAA can significantly alleviate the liver fatty degeneration induced by irinotecan; 2. significant synergistic anti-tumor effect: the tumor inhibition effect of the combination of 4HPAA and irinotecan is significantly better than that of the single-drug group; 3. high safety; and 4. great clinical transformation potential.

The invention provides a spleen-tonifying and detoxifying traditional Chinese medicine composition as well as a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition comprises a formula A and a formula B. The traditional Chinese medicine composition has a comprehensive conditioning effect and can relieve chemotherapy side effects, improve intestinal flora distribution, promote intestinal health, enhance the chemotherapy effect and improve the disease control rate. Wherein the formula A focuses on tonifying spleen and regulating qi, and improving nausea, vomiting and other symptoms at the initial stage of chemotherapy, and the formula B is added with medicines for clearing away heat and toxic materials and promoting blood circulation to remove blood stasis on the basis, is suitable for patients with myelosuppression with cancer toxicity residue, and strengthens the effects of clearing away heat and toxic materials and removing stasis; the composition has a multi-target action mechanism, and through the combined action of multiple ways, the treatment effect is enhanced, and the side effect is reduced.

This invention discloses an artificial intelligence deep learning model for predicting the sensitivity of neoadjuvant chemotherapy in colorectal cancer, belonging to the field of colorectal cancer treatment prediction technology. Its key technical points include the following steps: S1, data collection; S2, patient grouping; S3, screening predictive factors; S4, artificial neural network modeling; and S5, model validation. This invention successfully screens common clinical indicators for predicting the sensitivity of neoadjuvant chemotherapy in colorectal cancer and constructs an artificial neural network risk prediction model. This model can be applied to clinical practice, providing predictions for the sensitivity of neoadjuvant chemotherapy in colorectal cancer, thereby assisting clinicians in achieving more accurate predictions of chemotherapy efficacy. This invention helps optimize clinical treatment strategies, promotes the development of individualized neoadjuvant therapy regimens for colorectal cancer, and provides new ideas and methods for precision medicine.

The invention belongs to the technical field of biological medicines, and discloses a polydopamine modified celecoxib and cisplatin loaded dual drug-loading microsphere, which takes a polydopamine modified polyvinyl alcohol microsphere as a carrier, and the surface of the microsphere is loaded with celecoxib and cisplatin. Celecoxib and cis-platinum loaded on the dual drug-loading microspheres prepared by the invention have a good synergistic effect, and can significantly inhibit the excessive growth of liver cancer in blood vessels; when being applied to the liver cancer TACE operation, the compound has relatively high safety and high operation success rate, and can remarkably inhibit tumor cell proliferation so as to improve the embolization chemotherapy effect. The invention also discloses a preparation method of the dual drug-loading microsphere.

The application aims to provide a preparation method and application of an oral engineering probiotic system for producing active substances in situ metabolism of tumors. First, the probiotic is cultured, the CES gene is inserted into a plasmid as a target gene, the plasmid containing the CES gene is transfected into a probiotic competent cell by a heat shock method, the engineering probiotic capable of continuously and stably expressing carboxylesterase is obtained, and the oral engineering probiotic system is prepared by coating the engineering probiotic with a natural high molecular material, mercapto hyaluronic acid. The preparation method is scientific and reasonable, raw materials are abundant, and the preparation is easy to produce. The preparation method enhances the chemotherapy effect of colorectal cancer and reduces the toxic side effects caused by the distribution of chemotherapy drugs in other tissues and organs, provides new technical support for the treatment of colorectal cancer, is an innovation in oral microecological preparation drugs, and has great economic and social benefits.

The invention discloses targeted nanoparticles for breast cancer treatment as well as preparation and application thereof, and belongs to the technical field of biological medicines. The invention provides a three-mode synergistic anti-tumor strategy of chemotherapy-photothermal therapy-Fenton-like reaction mediated ferroptosis for the first time. The targeting nanoparticles are efficiently enriched in 4T1 breast cancer cells by virtue of the dual-targeting effect of the ET peptide and the EPR; in combination with photothermal therapy, the chemotherapy effect of PTX is remarkably enhanced, and proliferation, invasion and metastasis of tumor cells are effectively inhibited. Proteomics analysis finds that differential proteins are mainly enriched in motor proteins and ferroptosis pathways after intervention of the targeted nanoparticles, and a core mechanism of collaborative treatment is disclosed. Molecular docking proves that PTX and a key target protein receptor have specific interaction, and the multi-mode synergistic strategy provides an innovative technical platform for overcoming the limitation of traditional chemotherapy and developing an efficient and low-toxicity breast cancer treatment scheme.

The invention discloses a drug-loaded microneedle for synergistically treating tumors and preventing metastasis of the tumors and a preparation method and application thereof.The drug-loaded microneedle uses hyaluronic acid as a matrix to construct a soluble microneedle, superparamagnetic ferroferric oxide nanoparticles are loaded in the soluble microneedle, the ferroferric oxide nanoparticles carry active components, and the drug-loaded microneedle is prepared from the active components. Wherein the active component is a chemotherapeutic drug adriamycin or / and deoxyribonuclease I; under the action of a constant magnetic field, the ferroferric oxide nanoparticles realize magnetic targeting delivery and retention of active components; under an alternating magnetic field, the ferroferric oxide nanoparticles generate a magnetocaloric effect to promote quick release of active components, and tumor cell injury is induced through the magnetocaloric effect; the released chemotherapeutic drug doxorubicin is used for killing tumor cells, the chemotherapeutic drug doxorubicin and the magnetocaloric effect synergistically enhance the chemotherapeutic effect, and the released deoxyribonuclease I is used for degrading an over-expressed neutrophil extracellular trapping net in a tumor microenvironment, so that the microenvironment of tumor metastasis is destroyed.

The application discloses application of a vortioxetine and gemcitabine composition in preparation of a drug for resisting pancreatic cancer, and the composition is composed of vortioxetine and gemcitabine. The composition of the application can reduce the expression amount of MAOB protein, promote the apoptosis of pancreatic cancer cells, and synergistically increase the sensitivity of pancreatic cancer cell lines in vitro and pancreatic cancer mice in vivo to gemcitabine, so that the chemotherapy effect of pancreatic cancer cells which are resistant to gemcitabine is significantly improved after treatment by the composition. The composition of the application provides a new chemotherapy drug for pancreatic cancer cells which are resistant to gemcitabine treatment.

The invention provides an AUTAC bionic nano-particle as well as a preparation method and application of the AUTAC bionic nano-particle. The nanoparticle has a core-shell structure, and sequentially comprises a core, a functional peptide layer and a cell membrane shell from inside to outside, the core comprises a PLGA-PEG-Mal copolymer carrier, and entrapped temozolomide and cationic lipid DOTAP (Dioctyl Terephthalate); the functional peptide layer is formed by covalently connecting a multifunctional peptide with a maleimide group through sulfydryl; the cell membrane shell is a microcolloid cell membrane; the nanoparticles can efficiently pass through a blood brain barrier, are enriched at a brain tumor part in a targeted manner, reduce MGMT expression by degrading beta-catenin, reverse TMZ drug resistance and enhance a chemotherapy effect, and are suitable for treating temozolomide drug-resistant glioblastoma.

The invention relates to the technical field of biological medicine, in particular to an MTA3 small-molecule inhibitor and application thereof in sensitizing chemotherapy effect of gemcitabine pancreatic duct adenocarcinoma. The invention provides a small molecule MTA3i-01 which is obtained through high-throughput virtual screening and structure optimization. The micromolecule MTA3i-01 provided by the invention can specifically interfere with the combination of the MTA3 protein and the CRIP2 gene promoter region, and effectively recover the sensitivity of tumor cells to gemcitabine, thereby significantly enhancing the curative effect of chemotherapy. The tumor growth can be obviously inhibited by the combined treatment of the MTA3i-01 and the gemcitabine, the tumor growth is obviously inhibited by the combined treatment of the MTA3i-01 and the gemcitabine, the combined treatment is obviously superior to that of a gemcitabine single drug group and a MTA3i-01 single drug group, and obvious toxic reaction is not observed, so that the combined scheme has good in-vivo safety and synergistic curative effect.

The invention discloses Lactobacillus reuteri and an application thereof in preparation of a medicine for treating diffuse large B-cell lymphoma, and relates to the technical field of biological medicines. The invention provides an application of Lactobacillus reuteri and / or a metabolite of the Lactobacillus reuteri in preparation of a medicine for treating diffuse large B-cell lymphoma, the Lactobacillus reuteri is Lactobacillus reuteri HG001, the metabolite of the Lactobacillus reuteri HG001 is Lactobacillus reuteri HG001, the metabolite of the Lactobacillus reuteri HG001 is Lactobacillus reuteri HG001, and the metabolite of the Lactobacillus reuteri HG001 is Lactobacillus reuteri HG001. According to the application disclosed by the invention, the Lactobacillus reuteri is separated from faeces of healthy people and is used for preparing the medicine for treating the diffuse large B-cell lymphoma, and it is found that the Lactobacillus reuteri is confirmed as a probiotic strain for enhancing the chemotherapy effect of the diffuse large B-cell lymphoma and can improve side effects caused by treatment of the diffuse large B-cell lymphoma by cyclophosphamide; in addition, the Lactobacillus reuteri and cyclophosphamide have a synergistic effect when being used for treating the diffuse large B-cell lymphoma.

The invention discloses an application of circular RNA (Ribonucleic Acid) hascircRNA103812 (circ-NUP155) as a T lymphoblastic lymphoma / leukemia prognostic diagnosis or drug resistance prediction marker. According to the application disclosed by the invention, the specific high expression of circ-NUP155 in T-LBL / ALL refractory / recurrent patient tissues is found through screening for the first time; functional experiments verify that the overexpressed circ-NUP155 can significantly enhance proliferation of T-LBL / ALL cells in vitro and weaken cytotoxicity and apoptosis induced by Dox, and can directly cause resistance of transplanted tumors to Dox treatment in vivo, which indicates that the circ-NUP155 can be used as a novel molecular marker for predicting drug resistance of T-LBL / ALL chemotherapy drugs or prognosis diagnosis, and can be used as a novel molecular marker for predicting drug resistance of T-LBL / ALL chemotherapy drugs or prognosis diagnosis of T-LBL chemotherapy drugs by detecting the expression level of the circ-NUP155. The method can effectively evaluate the risk of chemotherapy resistance and predict survival prognosis, provides a basis for clinical decision-making, and provides a theoretical basis for developing novel targeted drugs or combined strategies for reversing drug resistance and improving existing chemotherapy curative effects.

The present invention relates to a dual drug delivery system having reversible antibody binding characteristics and stimulus responsiveness, and a method for manufacturing the same. The hydrogel-based microcapsule provided in the present invention has a chemical drug loaded inside the capsule and a fusion protein for antibody binding for immunotherapy on the outside, so that it can simultaneously perform immunotherapy and chemotherapy effects, and thus can be widely utilized in the development of pharmaceuticals for the treatment of various diseases.

This invention relates to an ovarian-targeted exosome loaded with antioxidants and its preparation method. The method involves constructing ovarian-targeted exosomes and then loading small-molecule antioxidants into these exosomes. This invention enables the targeted delivery of small-molecule antioxidants to the ovarian tissue of cancer patients before or during chemotherapy, protecting ovarian function without affecting the efficacy of chemotherapy for tumor cells, thus achieving ovarian function protection during chemotherapy.